Know Cancer

or
forgot password

Phase II Study With Rituximab and CHOP in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma


Phase 2
18 Years
N/A
Not Enrolling
Both
Primary Gastric Diffuse-Large B-Cell Lymphoma

Thank you

Trial Information

Phase II Study With Rituximab and CHOP in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma


see above


Inclusion Criteria:



- Age > 18 years

- Histologically confirmed primary gastric CD20+ DLBCL

- Written informed consent

- ECOG 0-2

Exclusion Criteria:

- Secondary aggressive Non-Hodgkin`s lymphoma involving the gastric area

- HIV positive patients

- Severe organ dysfunction

- Life expectancy of less than 3 months

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Complete remission rate

Outcome Time Frame:

at end of chemo-immunotherapy

Safety Issue:

No

Principal Investigator

Wolfram Brugger, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

64-03

NCT ID:

NCT00204659

Start Date:

March 2003

Completion Date:

September 2008

Related Keywords:

  • Primary Gastric Diffuse-Large B-Cell Lymphoma
  • Rituximab
  • CHOP
  • DLBCL
  • gastric lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Name

Location